Abstract
Aim:This study aimed to evaluate surgical and 5-year survival outcomes in patients undergoing sleeve lobectomy and bilobectomy after induction theraphy in treatment of lung cancer.
Methods:我们以单一为中心的研究包括2005年至2020年之间进行袖子叶切除术和屈骨切除术的265例肺癌患者。将患者分为两组,他们接受了新辅助治疗,而没有接受过新辅助治疗。回顾性研究了影响整体生存的所有变量。
Results:Of all 265 patients (245 male and 20 female), the mean age was 58.9 years (range: 19-78). Lobectomy was performed to 91.7%, and in 3% of all cases, video-assisted thoracoscopy was preferred. 81.9% of the tumors confirmed to be squamous cell subtype. In the 55 of patients (20,8%) who reiceved neoadjuvant theraphy, R0 resection was provided in all, however according to pathology reports, %3,3 of the patients who did not recieved neoadjuvant theraphy had incomplete resection. The 5-year survival rate was found to be 58.3%, and the median survival time was 80.1 months in all patients, patients with induction theraphy was %56,6 and %58,8 in patient without respectively. There was no significant diffirence statistically. In the cox-regression analysis, patient age, tumor size, lymph node metastasis and histology were determined as variables that affect survival (p< 0.05 for all variables).
Conclusions:在这项研究中,我们回顾了新辅助治疗后,我们对这些大量患者进行了新辅助疗法后的外科手术结局。我们发现新辅助治疗不是袖子切除术中生存的重要因素。
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3861.
该摘要是在2021年的国际大会上发表的,该会议“预测COPD患者的恶化”。
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available atwww.ers-education.org(ERS member access only).
- 版权所有©作者2021